Disease Subtype–Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A

Journal of the National Cancer Institute

Volumn 109, Issue 6, 2017, Pages

  Samanta, Suman K ^a   Sehrawat, Anuradha ^a   Kim, Su Hyeong ^a   Hahm, Eun Ryeong ^a   Shuai, Yongli ^a,b   Roy, Ruchi ^a   Pore, Subrata K ^a   Singh, Krishna B ^a   Christner, Susan M ^a,b   Beumer, Jan H ^b   Davidson, Nancy E ^a,b   Singh, Shivendra V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; CYTOKINE; DNA NUCLEOTIDYLEXOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; METHYLNITROSOUREA; PHYTOCHEMICAL; REACTIVE OXYGEN METABOLITE; WITHAFERIN A; 8-OXO-7-HYDRODEOXYGUANOSINE; ACETYL COENZYME A; DEOXYGUANOSINE; FORKHEAD TRANSCRIPTION FACTOR; FOXQ1 PROTEIN, RAT; KI 67 ANTIGEN; LACTIC ACID; LEPTIN; MALIC ACID; MALIC ACID DERIVATIVE; RALDH1 PROTEIN, RAT; RETINAL DEHYDROGENASE; TUMOR MARKER; UBIQUINOL CYTOCHROME C REDUCTASE; WITHANOLIDE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AYURVEDA; BREAST CANCER; CANCER STEM CELL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FLOW CYTOMETRY; HOMEOSTASIS MODEL ASSESSMENT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MITOSIS INHIBITION; MOUSE MAMMARY TUMOR VIRUS; NONHUMAN; PROTEIN EXPRESSION; RAT; RAT MODEL; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; STUDENT T TEST; TUMOR WEIGHT; TUMOR XENOGRAFT; TUNEL ASSAY; WITHANIA SOMNIFERA; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BLOOD; BREAST NEOPLASMS; CELL CYCLE; CHEMICALLY INDUCED; CHEMISTRY; COMPLICATION; DRUG EFFECTS; FEMALE; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MITOSIS; MITOSIS INDEX; MOUSE; PATHOLOGY; RETROVIRUS INFECTION; TUMOR VOLUME; VIROLOGY; VIRUS INFECTION;

ACETYL COENZYME A; ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL CYCLE; CYTOKINES; DEOXYGUANOSINE; ELECTRON TRANSPORT COMPLEX III; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KI-67 ANTIGEN; LACTIC ACID; LEPTIN; MALATES; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MCF-7 CELLS; METHYLNITROSOUREA; MICE; MITOSIS; MITOTIC INDEX; RATS; RECEPTORS, ESTROGEN; RETINAL DEHYDROGENASE; RETROVIRIDAE INFECTIONS; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR VIRUS INFECTIONS; WITHANOLIDES;

EID: 85021014938     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw293     Document Type: Article

References (50)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7–30.
2. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
3. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393–10398.
4. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012;12(12):835–848.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388.
6. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65(2):125–134.
7. Goss PE, Ingle JN, Alés-Martınez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–2391.
8. Mallick S, Benson R, Julka PK. Breast cancer prevention with anti-estrogens: Review of the current evidence and future directions. Breast Cancer. 2016; 23(2):170–177.
9. Stan SD, Kar S, Stoner GD, Singh SV. Bioactive food components and cancer risk reduction. J Cell Biochem. 2008;104(1):339–356.
10. Gullett NP, Rahul Amin ARM, Bayraktar S, et al. Cancer prevention with natural compounds. Semin Oncol. 2010;37(3):258–281.
11. Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer. 2011;11(3):211–218.
12. Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactone. AAPS J. 2014;16(1):1–10.
13. Shohat B, Gitter S, Abraham A, Lavie D. Antitumor activity of withaferin A (NSC-101088). Cancer Chemother Rep.1967;51(5):271–276.
14. Antony ML, Lee J, Hahm ER, et al. Growth arrest by the antitumor steroidal lactone withaferin A in human breast cancer cells is associated with downregulation and covalent binding at cysteine 303 of b-tubulin. J Biol Chem. 2014; 289(3):1852–1865.
15. Stan SD, Hahm ER, Warin R, Singh SV. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. 2008;68(18):7661–7669.
16. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One. 2011;6(8):e23354.
17. Hahm ER, Lee J, Kim SH, et al. Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model. J Natl Cancer Inst. 2013;105(15):1111–1122.
18. Hahm ER, Lee J, Huang Y, Singh SV. Withaferin A suppresses estrogen receptor-a expression in human breast cancer cells. Mol Carcinog. 2011;50(8):614–624.
19. Hahm ER, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression. Cancer Lett. 2013;334(1):101–108.
20. Hahm ER, Lee J, Singh SV. Role of mitogen-activated protein kinases and Mcl-1 in apoptosis induction by withaferin A in human breast cancer cells. Mol Carcinog. 2014;53(11):907–916.
21. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest. 1990;62(3):244–278.
22. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Gene expression profiling of NMU-induced rat mammary tumors: Cross species comparison with human breast cancer. Carcinogenesis. 2005;26(8):1343–1353.
23. Smolarek AK, So JY, Burgess B, et al. Dietary administration of d- and c-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor-positive, but not HER-2 breast cancer. Cancer Prev Res (Phila). 2012;5(11): 1310–1320.
24. Singh SV, Kim SH, Sehrawat A, et al. Biomarkers of phenethyl isothiocyanate-mediated mammary cancer chemoprevention in a clinically relevant mouse model. J Natl Cancer Inst. 2012;104(16):1228–1239.
25. Powolny AA, Bommareddy A, Hahm ER, et al. Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst. 2011;103(7):571–584.
26. Kim SH, Singh SV. Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells. Cancer Prev Res (Phila). 2014;7(7):738–747.
27. Lee J, Hahm ER, Singh SV. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis. 2010;31(11):1991–1998.
28. Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat. 2012;136(1): 45–56.
29. Thompson HJ, Adlakha H. Dose-responsive induction of mammary gland carcinomas by the intraperitoneal injection of 1-methyl-1-nitrosourea. Cancer Res. 1991;51(13):3411–3415.
30. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987;47(15):4020–4024.
31. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis. 1994;15(12): 2775–2780.
32. O’Brien CS, Farnie G, Howell SJ, Clarke RB. Breast cancer stem cells and their role in resistance to endocrine therapy. Horm Cancer. 2011;2(2):91–103.
33. Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi SC, Yu Q. FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res. 2011;71(8): 3076–3086.
34. Kim SH, Kaschula CH, Priedigkeit N, Lee AV, Singh SV. Forkhead box Q1 is a novel target of breast cancer stem cell inhibition by diallyl trisulfide. J Biol Chem. 2016;291(26):13495–13508.
35. Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N, Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: A prospective study. Cancer Epidemiol Biomarkers Prev. 2013;22(7): 1319–1324.
36. Romero-Figueroa Mdel S, Garduño-Garcıa Jde J, Duarte-Mote J, Matute-Gonzalez G, Gomez-Villanueva A, De la Cruz-Vargas J. Insulin and leptin levels in obese patients with and without breast cancer. Clin Breast Cancer. 2013; 13(6):482–485.
37. Delort L, Rossary A, Farges MC, Vasson MP, Caldefie-Chézet F. Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity. Life Sci. 2015;140:37–48.
38. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, Leneveu MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2002;293(1):622–628.
39. Thaiparambil JT, Bender L, Ganesh T, et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin dis-assembly and serine 56 phosphorylation. Int J Cancer. 2011;129(11):2744–2755.
40. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50(4):219–244.
41. Zhang H, Meng F, Liu G, et al. Forkhead transcription factor Foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011;71(4):1292–1301.
42. Ross JB, Huh D, Noble LB, Tavazoie SF. Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat Cell Biol. 2015;17(5):651–664.
43. Lee J, Hahm ER, Marcus AI, Singh SV. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. Mol Carcinog. 2015;54(6):417–429.
44. Zheng Q, Dunlap SM, Zhu J, et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011;18(4):491–503.
45. Mauro L, Catalano S, Bossi G, et al. Evidences that leptin up-regulates E-cadherin expression in breast cancer: Effects on tumor growth and progression. Cancer Res. 2007;67(7):3412–3421.
46. Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011;8(5):263–275.
47. Carroll PA, Healy L, Lysaght J, et al. Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. Mol Carcinog. 2011;50(8):643–651.
48. Suman S, Das TP, Moselhy J, et al. Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model. Oncotarget. 2016;7(33): 53751–53761.
49. Agnihotri AP, Sontakke SD, Thawani VR, Saoji A, Goswami VS. Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study. Indian J Pharmacol. 2013;45(4):417–418.
50. Patel SB, Rao NJ, Hingorani LL. Safety assessment of Withania somnifera extract standardized for withaferin A: Acute and sub-acute toxicity study. J Ayurveda Integr Med. 2016;7(1):30–37.‘